PLASMA protein therapeutics company, CSL Behring, said it will present study data from three ongoing clinical trial programs evaluating the company's novel recombinant factor VIIa (rVIIa-FP), VIII (rVIII-SingleChain) and IX (rIX-FP) agents for people with hemophilia A and B with and without inhibitors. The data will be presented at the International Society on Thrombosis and Haemostasis (ISTH) congress in Amsterdam.
CSL Behring is the only company pursuing longer-acting rVIIa-FP and rIX-FP candidates based on recombinant albumin, and a rVIII-SingleChain compound that has been shown to improve the stability and half-life of factor VIII (FVIII).
"We are steadily advancing an exciting clinical development program to evaluate novel longer-acting recombinant factor therapies to progress the care of people with hemophilia A and B," said Russell Basser, M.D., CSL Senior Vice President, Global Clinical Research & Development. "CSL Behring has a long history and proven expertise developing and delivering valuable therapies for the hemophilia community. Now, we look forward to providing updates on our promising recombinant pipeline, which includes innovative candidates for rVIIa-FP, rVIII-SingleChain and rIX-FP, at this meeting." CSL Behring is advancing its recombinant factor development program in collaboration with its parent company, CSL Limited (ASX: CSL).
Information on the studies to be presented is as follows:
Monday, July 1, 2013
- The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Potently Improves Outcome After Cerebral Ischemia/Reperfusion Injury in Rats (J. Krupka, et al.) E-Poster #PA 1.10-2: 5:00 p.m. - 6:30 p.m.
- Inhibiting Coagulation Factor XIIa Potently Prevents Thrombosis in a Rabbit Arteriovenous Shunt Model (M. Fries, et al.) E-Poster #PA 1.10-4: 5:00 p.m. - 6:30 p.m.
- The FXIIa Inhibitor rHA-Infestin-4 Safely Protects from Arterial and Venous Thrombosis in Rodent and Non-Rodent Species (F. May, et al.) E-Poster #PA 1.10-6: 5:00 p.m. - 6:30 p.m.
- Quantitative Whole Body Autoradiography (QWBA) Study on the Effect of Albumin Fusion on the Biodistribution of Recombinant Factor rFIX (E. Herzog, et al.) E-Poster #PA 1.12-1: 5:00 p.m. - 6:30 p.m.
- Functional Characterization of rVIII-SingleChain and Comparison with Commercially Available Recombinant FVIII Products (C. Horn, et al.) E-Poster #PB 1.55-6: 5:00 p.m. - 6:30 p.m.
- Quantitative Whole Body Autoradiography (QWBA) Study on the Biodistribution of a Recombinant Factor rVIIa Linked to Human Albumin (E. Herzog, et al.) E-Poster #PB 1.58-3: 5:00 p.m. - 6:30 p.m.